Treatment guidelines for bladder cancer have changed significantly in recent years, due to the introduction of effective new drug combinations to treat the disease.
Greg Glasgow
CU Anschutz
Anschutz Cancer Pavilion
1665 North Aurora Court
2004
Aurora, CO 80045
Research Bladder Cancer Clinical Trials
Treatment guidelines for bladder cancer have changed significantly in recent years, due to the introduction of effective new drug combinations to treat the disease.
Research that began at the University of Colorado Cancer Center may help doctors better treat patients with non-muscle invasive bladder cancer.
Community Prostate Cancer Bladder Cancer Kidney Cancer Testicular cancer
It’s one thing to develop cancer treatment guidelines in the U.S., where even the smallest health centers have access to the same basic technology for treatment and testing. But what about creating guidelines for oncologists in Sub-Saharan Africa, where access to medical resources can be limited and the disease can present differently?
Awareness Bladder Cancer Urology
In its early stages, bladder cancer can be easy to ignore or write off as something it isn’t – a UTI, a bladder infection, or other conditions that are commonly treated with an antibiotic.
The median age for receiving a bladder cancer diagnosis is 73, and a significant number of those living with the disease are in their 70s and 80s.
University of Colorado Cancer Center member Janet Kukreja, MD, assistant professor of urology in the University of Colorado School of Medicine, is taking part in this weekend’s Walk to End Bladder Cancer along with her office staff, fellow physicians, and even some of her patients. For this year’s “virtual” event, hosted by the Bladder Cancer Advocacy Network to kick off Bladder Cancer Awareness Month in May, participants walk in their own cities at their own pace, sharing their progress with others around the country.
Patient Care Bladder Cancer Cancer
“Have you ever had a dream when you wake up and everything is just kind of vibrating? It doesn’t make any sense but it kind of points the way?” asks Fort Collins artist and musician, Shelley Kerr.
University of Colorado Cancer Center led clinical trial data show that a predictive tool called COXEN may show which bladder cancer patients will respond to pre-surgical chemotherapy, a step towards allowing doctors to offer such chemotherapy to patients likely to respond, while moving more efficiently to other treatment options with patients unlikely to benefit. Results will be presented Monday, June 3 at 8:00am as oral abstract at the 2019 American Society for Clinical Oncology (ASCO) Annual Meeting (ASCO abstract #4506).
Cure Today
July 12, 2024
University of Colorado Cancer Center member Dr. Steven Thorpe emphasizes the collaborative nature of treating soft tissue and bone sarcomas, highlighting the multidisciplinary efforts at CU School of Medicine's Department of Orthopedics and Children’s Hospital Colorado. He underscores the goal of not only curing the disease but also preserving function through advanced surgical techniques and modern therapies, ensuring patients maintain quality of life post-treatment. Thorpe stresses the importance of long-term outcomes, tailoring treatments to support patients’ aspirations beyond their cancer journey, especially for pediatric cases.
OncLive
July 08, 2024
CU Cancer Center member S. Lindsey Davis, MD, highlighted that the combination therapy of sapanisertib and alisertib showed marginal clinical benefit for patients with advanced solid tumors, correlative analyses suggested that apoptotic response and tumor immune cell infiltrate might influence clinical outcomes. The phase 1b study's expansion cohort indicated some positive outlying responses among patients and underscore the need for further research to tailor treatments for standout patients and explore rational combinations to enhance efficacy.
News Medical
June 19, 2024
A new study led by University of Colorado Cancer Center member Marco Del Chiaro, MD, PhD, reveals that nearly 5% of pancreatic adenocarcinoma patients achieved a pathological complete response (pCR) after pre-surgical chemotherapy or chemoradiotherapy. This significant finding indicates that patients with pCR have a 63% five-year survival rate, compared to 30% for those without pCR, suggesting the potential for tailored treatments to improve outcomes.
Cancer Network
June 14, 2024
In a conversation at the 2024 European Hematology Association Congress, CU Cancer Center member Manali Kamdar, MD, discussed potential future research on lisocabtagene maraleucel (liso-cel; Breyanzi) for mantle cell lymphoma (MCL) and other lymphoma subgroups. She highlighted findings from the phase 1 TRANSCEND NHL 001 trial, noting improved efficacy and safety in patients with fewer prior therapies and non-refractory disease, suggesting liso-cel's utility in earlier treatment lines and specific lymphoma subgroups.